Clinical Trial Update: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating REC-2282 in progressive NF2-mutated meningiomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma
• Neurofibromatosis Type

Drugs mentioned

• REC-2282 (REC-2282)

Snippet

Sponsor: Recursion Pharmaceuticals Inc. | Conditions: Neurofibromatosis Type 2 | Phase 2, Phase 3 | Status: TERMINATED